Innovent Biologics, Inc. (HKEX: 01801), a China-based biopharmaceutical company announced on Saturday that it has updated the Phase 1b efficacy and safety results of IBI939 (anti-TIGIT antibody) combined with sintilimab (anti-PD-1 antibody) in earlier untreated PD-L1-selected NSCLC without sensitising mutations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
IBI939, an IgG4k recombinant fully human anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) monoclonal antibody, has been developed by Innovent Biologics.
This Phase 1b study is intended to assess safety, tolerability, and efficacy of combination therapy of IBI939 with sintilimab in subjects with previously untreated, locally advanced unresectable or metastatic PD-L1 TPS greater than or equal to 50 NSCLC without sensitising mutations (clinicalTrials.gov, NCT04672369).
Effective 1 January 2023, 42 pts were randomised (2:1) to receive IBI939 and sintilimab (experimental arm, n=28) or sintilimab monotherapy (control arm, n=14).
The study results revealed median progression free survival (PFS) follow-up of 12.2 months in the experimental arm and 11.3 months in the control arm, respectively, median PFS per investigator was 13.2 months (95% CI: 6.7-16.5) and 6.4 months (95% CI: 1.4-NA), and the hazard ratio (HR) between two arms was 0.62. It also indicated that 96.4% of subjects in the experimental arm and 71.4% of subjects in the control arm experienced treatment-related adverse event (TRAE). Each arm occurred one treatment-emergent adverse event (TEAE) resulting in the end of treatment, and no TEAE leading to death occurred in the experimental arm.
Outcome from this updated evaluation following longer follow-up indicated that IBI939 plus sintilimab combination therapy had continued efficacy and manageable safety profile in previously untreated PD-L1 TPS greater than or equal to 50% NSCLC without sensitising mutations.
SCG releases SCG101 late-breaking clinical data in HBV-related hepatocellular carcinoma
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
Ajinomoto and RIBOMIC announce successful extension of nucleic acid aptamer pharmacokinetics
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Odylia Therapeutics undertakes gene replacement therapy project for NPHP1 retinal dystrophy
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial